Your shopping cart is currently empty

Tat-braftide is a peptide inhibitor designed to block the dimerization of BRAF, thereby inhibiting its kinase activity. After disrupting BRAF dimers, Tat-braftide facilitates proteasomal degradation of BRAF proteins, directly reducing BRAF kinase activity and diminishing MAPK pathway activation. Tat-braftide is useful for studying RAF kinase function within the MAPK signaling pathway and researching BRAF-mutant cancers.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | Tat-braftide is a peptide inhibitor designed to block the dimerization of BRAF, thereby inhibiting its kinase activity. After disrupting BRAF dimers, Tat-braftide facilitates proteasomal degradation of BRAF proteins, directly reducing BRAF kinase activity and diminishing MAPK pathway activation. Tat-braftide is useful for studying RAF kinase function within the MAPK signaling pathway and researching BRAF-mutant cancers. |
| Formula | C128H227N51O30S |
| Sequence | Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Pro-Gln-{PEG2}-Thr-Arg-His-Val-Asn-Ile-Leu-Leu-Phe-Met |
| Sequence Short | GRKKRRQRRRPQ-{PEG2}-TRHVNILLFM |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.